Ignite Creation Date:
2024-05-06 @ 6:49 PM
Last Modification Date:
2024-10-26 @ 2:55 PM
Study NCT ID:
NCT05792943
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-03-31
First Post:
2023-03-20
Brief Title:
UGT1A1 Genotyping in Taiwanese Cancer Patients
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Impact of Routine UGT1A1 Genotyping Before Irinotecan Chemotherapy in Taiwanese Cancer Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Irinotecan is commonly used to treat lung colorectal pancreatic stomach esophageal and other types of cancer The main metabolic pathway of SN-38 the active product of Irinotecan is grape glycoalkaloid acidification by UDP - glucuronosyltransferase UGT1A1 and then excreted through bile and urine Clinically Irinotecan treatment can cause many adverse reactions and differences in UGT1A1 genotypes can lead to structural changes or functional defects in enzymes causing reduced acidification of grape glycolaldehyde and increasing Irinotecan side effects Therefore if the patients ability to metabolize the drug can be assessed before taking the drug it will be of great help in treatment
Until 2021 cancer will remain the top ten causes of death in Taiwan of which colorectal and pancreatic cancer rank third and seventh among the top ten cancers in Taiwan respectively and these two cancers often use complex chemotherapy including irinotecan Routine detection of UGT1A1 genotype in patients with colorectal and pancreatic cancer before irinotecan treatment predicts the drug metabolism capacity of irinotecan and adjusts the dose allowing patients receiving irinotecan to reduce the harm of side effects At present the UGT1A1 genotype evaluated is usually only UGT1A128 but the common UGT1A1 genotype in Taiwan also has UGT1A16 and UG1A163 etc There is no literature on Taiwanese cancer patients with actual irinotecan chemotherapy so this study aims to explore the influence of the UGT1A1 genotype and develop other UGT1A1 genotype test methods It is expected that molecular testing tools can improve cancer precision medicine and provide personalized medicine
Until 2021 cancer will remain the top ten causes of death in Taiwan of which colorectal and pancreatic cancer rank third and seventh among the top ten cancers in Taiwan respectively and these two cancers often use complex chemotherapy including irinotecan Routine detection of UGT1A1 genotype in patients with colorectal and pancreatic cancer before irinotecan treatment predicts the drug metabolism capacity of irinotecan and adjusts the dose allowing patients receiving irinotecan to reduce the harm of side effects At present the UGT1A1 genotype evaluated is usually only UGT1A128 but the common UGT1A1 genotype in Taiwan also has UGT1A16 and UG1A163 etc There is no literature on Taiwanese cancer patients with actual irinotecan chemotherapy so this study aims to explore the influence of the UGT1A1 genotype and develop other UGT1A1 genotype test methods It is expected that molecular testing tools can improve cancer precision medicine and provide personalized medicine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None